The INTERCEPT Blood System for platelets and plasma is an FDA approved pathogen reduction system that reduces the risk of transfusion-transmitted infection by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. INTERCEPT targets nucleic acids to inactivate and prevent further replication of established transfusion threats, such as HBV, HCV, HIV, WNV, and bacteria, as well as emerging pathogens such as chikungunya and dengue. The INTERCEPT red blood cell system is in clinical development.